Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
about
Graft-versus-host disease biomarkers: omics and personalized medicineGraft-versus-host disease: why have we not made more progress?A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.Transplantation-Associated Thrombotic Microangiopathy in Patients Treated With Sirolimus and Cyclosporine as Salvage Therapy for Graft-Versus-Host Disease.Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosisA phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL).Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation.Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT.(90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma.A phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients.Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant.Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT.Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus/sirolimus-based GVHD prophylaxisThe addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trialPharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate.Sirolimus as primary treatment of acute graft-versus-host disease following allogeneic hematopoietic cell transplantation.Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention.Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantatProgress and prospects: graft-versus-host disease.Immune modulation of inflammatory conditions: regulatory T cells for treatment of GvHD.Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: considerations for evidence-based GVHD prophylaxis.Time now to TORC the TORC? New developments in mTOR pathway inhibition in lymphoid malignancies.The efficacy and safety of sirolimus-based graft-versus-host disease prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials.Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood TransplantationGVHD prophylaxis with sirolimus-tacrolimus may overcome the deleterious effect on survival of HLA mismatch after reduced-intensity conditioning allo-SCT.Rapamycin preconditioning attenuates transient focal cerebral ischemia/reperfusion injury in mice.
P2860
Q26824540-EF26F8C8-5F3E-4BA1-BD3E-2FABBF60B2CEQ27012940-912B1FF3-FA36-4364-957A-5300D94CAC6DQ33387336-D7B33DA7-532B-4A54-AB95-B279981BB0EAQ33424311-51EF485B-D413-4A8B-8E0F-C7FE45F53EDCQ33643387-48D4FC3F-C35D-47D0-9D78-925DBBB635ABQ33924570-771D4934-37F9-4F87-963F-AEEAD18D3C5FQ34077792-CE5221AD-259A-4CC8-8FC6-CE8EF603B376Q34272554-83BAC812-8C99-4B2C-BFF2-0AB5932B5973Q34860077-267D9B93-E353-47B6-8CD3-1E6B097EEAD8Q35115650-4A8E3437-9BCB-4961-8E30-C83FE5FE6C52Q35218515-45A452DA-82FF-4A07-9FD4-A8E96FFD3C16Q35231363-4114FA6A-26B3-4B8A-91A6-2691053C9048Q35231368-5074C10A-BC68-4FA3-872D-CAA4F7DECFF3Q36206849-704D62F2-C0A3-4409-8F3C-AAB50A688B60Q36734547-5AAF1588-3C82-46EC-9A8F-50B45B42B5FDQ36777485-720D31AB-D22B-4F7F-8264-C02FF4EA9040Q36862464-D03E681B-2ADE-461B-A460-CAB2AD8AEB76Q36868082-EC7D1854-A02A-4E11-A51B-043375AF99BAQ36925951-807678FE-827F-43DC-930E-3730B158A721Q37238884-0ECC5F8E-C3FA-438E-AD11-3F1D1136043CQ37761297-F7463A2B-46D0-41B2-9BDC-15989209676EQ37993738-3A2637F5-BF73-46BF-AD06-50AED93AE1D1Q38202155-66F19337-9AE0-456E-A257-E511C78B5370Q38212951-04B4A0F8-1BC0-43ED-AC38-31B19242D791Q38413246-963BE894-03A2-4BA8-9F7D-0EE24AC3105CQ40577820-62BA7DCB-0364-4956-886B-E6077E3F60E6Q48261069-C5EC1A70-5347-4600-9474-BDC82A6E90E0Q48406263-235267BA-31A9-4152-99C4-3BE856C61E2A
P2860
Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Sirolimus, tacrolimus, and low ...... ood stem cell transplantation.
@en
Sirolimus, tacrolimus, and low ...... ood stem cell transplantation.
@nl
type
label
Sirolimus, tacrolimus, and low ...... ood stem cell transplantation.
@en
Sirolimus, tacrolimus, and low ...... ood stem cell transplantation.
@nl
prefLabel
Sirolimus, tacrolimus, and low ...... ood stem cell transplantation.
@en
Sirolimus, tacrolimus, and low ...... ood stem cell transplantation.
@nl
P2093
P2860
P1476
Sirolimus, tacrolimus, and low ...... ood stem cell transplantation.
@en
P2093
Corey Cutler
Edwin P Alyea
Haesook T Kim
Joseph H Antin
Robert J Soiffer
Vincent Ho
P2860
P304
P356
10.1016/J.BBMT.2008.05.024
P577
2008-08-01T00:00:00Z